Results 201 to 210 of about 25,216 (236)

Advances and future perspectives in chimeric antigen receptor T-cell and bispecific antibody therapies for multiple myeloma. [PDF]

J Clin Exp Hematop
Suzuki T, Iida S.
europepmc   +1 more source

Successful Treatment of Diffuse Large B-Cell Lymphoma and Antisynthetase Syndrome with Bispecific Antibody Glofitamab. [PDF]

Cancer Manag Res
Wei C, Zhang M, Zhao D, Zhang W, Zhang Y.   +4 more
europepmc   +1 more source

Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design. [PDF]

Antib Ther
Wang M, Xu Q, Kong Y, Zhong Y, Yin F, Liu L, Yang Z, Ying T, Wu Y.   +8 more
europepmc   +1 more source

Radiologic Pseudoprogression Associated With a Positive Response in a Patient With Multiple Myeloma Treated With a BCMA×CD3 Bispecific Antibody: A Case Report. [PDF]

EJHaem
Khan AM, Kroog GS, Roccia T, Knorr K, Boyapati A, Bumma N.   +5 more
europepmc   +1 more source

Bispecific antibody targeting shared indel-derived neoantigen of APC. [PDF]

Front Immunol
Effenberger C, Wu X, Zhao P, Matsumoto S, Nakamura Y, Kiyotani K.   +5 more
europepmc   +1 more source

Novel tetravalent bispecific antibody, PSMA/TRAIL‑R2 REGULGENT™, induces selective tumor cell apoptosis without hepatotoxicity. [PDF]

Oncol Rep
Nakayama M, Takagi-Maeda S, Machino Y, Nihira K, Inoue M, Takahashi N, Usami K.   +6 more
europepmc   +1 more source

A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer. [PDF]

Cancer Chemother Pharmacol
Hudson A, Jayaram A, Garmezy B, Zorko NA, Zarrabi KK, Mathews L, Rupnow B, Li M, Ghosh D, Urtishak K, Francis P, Wang SC, Attiyeh E, de Bono J.   +13 more
europepmc   +1 more source

The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma. [PDF]

Front Med (Lausanne)
Zhou X, Luo E, Chen W, Deng Y, Wu B, Jiang X, Zhang K, Lai F.   +7 more
europepmc   +1 more source

Cadonilimab (PD-1/CTLA-4 bispecific antibody) combination therapy for driver gene-negative advanced NSCLC: a single-center retrospective real-world study. [PDF]

Front Oncol
Zeng L, Xiang Y, Sun A, Lu K.
europepmc   +1 more source

Structure-guided bispecific antibody engineering confers broad protection against KP.3.1.1 and sarbecoviruses. [PDF]

iScience
Ma Y, Liu Q, Rehati P, Zhang Z, Wang Y, Liu Z, Chen J, Bai X, Hao A, Wang Y, Wen Y, Chen Z, Lu L, Zhao J, Wu F, Sun L, Huang J.   +16 more
europepmc   +1 more source